Metabolites and bioequivalence: Past and present

Clinical Pharmacokinetics

Volumn 43, Issue 10, 2004, Pages 655-672

  Jackson, Andre J ^a   Robbie, Gabriel ^a   Marroum, Patrick ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMITRIPTYLINE; AMOXAPINE; CANRENONE DERIVATIVE; CYCLOSPORIN; CYTOCHROME P450 3A; DICOUMAROL; DIHYDROERGOCRYPTINE; DIMETHYLSELEGILINE; DOXEPIN; DRUG METABOLITE; LOXAPINE; METHAMPHETAMINE; MIDAZOLAM; OSELTAMIVIR; PHENOBARBITAL; PROCAINAMIDE; RIFAMPICIN; SELEGILINE; SPIRONOLACTONE; THIORIDAZINE; UNCLASSIFIED DRUG; VERAPAMIL;

AREA UNDER THE CURVE; BIOEQUIVALENCE; CANADA; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG FORMULARY; DRUG METABOLISM; DRUG RELEASE; DRUG SCREENING; ENZYME INDUCTION; FOOD AND DRUG ADMINISTRATION; FRACTIONATION; HUMAN; HYDROLYSIS; KIDNEY CLEARANCE; LIVER METABOLISM; LOW DRUG DOSE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

ANIMALS; BIOTRANSFORMATION; DIGESTIVE SYSTEM; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL; THERAPEUTIC EQUIVALENCY;

EID: 3242772217     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200443100-00002     Document Type: Review

References (39)

1. Food and Drug Administration. Guidance for in-vivo bioequivalence study and in-vitro dissolution testing for allopurinol tablets. Rockville (MD): Food and Drug Administration, 1985
2. Food and Drug Administration. Guidance for a protocol for conducting in-vivo bioequivalence study and in-vitro dissolution testing for immediate-release flurazepam hydrochloride capsules. Rockville (MD): Food and Drug Administration, 1985
3. Food and Drug Administration. Guidance for a protocol to conduct a bioequivalence study on loxapine succinate capsules. Rockville (MD): Food and Drug Administration, 1987
4. Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products - general considerations. Rockville (MD): Food and Drug Administration, 2000 Oct 27
5. Chen ML, Jackson AJ. The role of metabolites in bioequivalency assessment: I. linear pharmacokinetics without first-pass effect. Pharm Res 1991; 8: 25-32
6. Chen ML, Shah V, Patnaik R, et al. Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res 2001; 18: 1645-50
7. Holford N. Pharmacodynamics and bioequivalence. In: Jackson AJ, editor. Generics and bioequivalence. Boca Raton (FL): CRC Press, 1994: 87-100
8. Guitton C, Kinowski JM, Abbar M, et al. Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia. J Clin Pharmacol 1999 Jul; 39 (7): 721-8
9. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999 Dec; 37 (6): 471-84
10. Hossain M, Jhee SS, et al. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. Clin Pharmacokinet 2002; 41 (3): 225-34
11. O'Reilly RA, Aggeler PM, Leong LS. Studies on the coumarin anticoagulant drugs: a comparison of the pharmacodynamics of dicumarol and warfarin in man. Thromb Diath Haemorrh 1964; 11: 1-22
12. Midha KK, Hubbard JW, McKay G, et al. The role of metabolites in a bioequivalence study II: amoxapine, 7-hydroxyamoxapine, and 8-hydroxyamoxapine. Int J Clin Pharmacol Ther 1999; 37 (9): 428-38
13. Pratt CM, Mason J, Russell T, et al. Cardiovascular safety of fexofenadine HCl. Am J Cardiol 1999 Nov 15; 84 (10): 1278-9
14. Turnheim K, Krivanek P, Oberbauer R, et al. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. Br J Clin Pharmacol 1991; 48 (4): 501-9
15. Pelkonen O, Boobis AR, Gundert-Remy U, et al. In vitro prediction of gastrointestinal absorption and bioavailability: an experts meeting report. Eur J Clin Pharmacol 2001; 57: 621-9
16. Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60: 14-24
17. Albert KS. Analytical issues in bioequivalency determinations: importance of metabolites in bioequivalence. In: McGilvery IJ, Dighe SV, French IW, et al., editors. Proceedings Bio International 89; 1989 Oct 1-4; Toronto: 96-8
18. Houston JB. Metabolites. In: McGilvery IJ, Dighe SV, French IW, et al., editors. Proceedings Bio International 89; 1989 Oct 1-4; Toronto: 99-100
19. Midha KK, McGilvery IJ, Hubbard JW, et al. Panelist presentation. In: McGilvery JJ, Dighe SV, French IW, et al., editors. Proceedings Bio International 89; 1989 Oct 1-4; Toronto: 101-6
20. Dighe SV, Patnaik RN. Need for metabolite analysis in bioequivalence studies. In: Blume HH, Midha KK, editors. Bio-International 92. Bad Homburg: Medpharm, 1993: 149-61
21. Tucker GT, Rostami A, Jackson PA, et al. Metabolite measurements in bioequivalence studies: theoretical considerations. In: Blume HH, Midha KK, editors. Bio-International 92. Bad Homburg: Medpharm, 1993: 163-70
22. McGilvery IJ, Ormsby E. Metabolite measurements in bioequivalence studies: examples and problems I. In: Blume HH, Midha KK, editors. Bio-International 92. Bad Homburg: Medpharm, 1993: 171-88
23. Balant LP, Gex-Fabry M. Metabolite measurements in bioequivalency studies: regulatory aspects. In: Blume HH, Midha KK, editors. Bio-International 92. Bad Homburg: Medpharm, 1993: 197-207
24. Blume HH, Midha KK. Report of consensus meeting: Bio-International 92, conference on bioavailability, bioequivalence and pharmacokinetic studies: session III. Eur J Pharm Sci 1993; 1: 165-70
25. Blume HH, Midha KK. Bio-International 92, conference on bioavailability, bioequivalence and pharmacokinetic studies. J Pharm Sci 1993; 82: 186-1189
26. Walter-Sack I, de Vries JX, Kreiner C, et al. Bioequivalence of allopurinol preparations: to be assessed by the parent drug or active metabolite? Clin Pharmacol 1993; 71: 240-6
27. Midha KK, Hubbard JW, McKay G, et al. The role of metabolites in a bioequivalence study 1: loxapine, 7-hydroxyloxapine and 8-hydroxyloxapine. Int J Clin Pharmacol 1993; 31: 177-83
28. Hutt V, Sauter K. Bioequivalence evaluation of the metabolites 1,2 and 1,3 glyceryl dinitrate of two different glyceryl trinitrate patches after usage in healthy volunteers. Arzneimittel Forschung 1994; 44: 1313-7
29. Chen ML, Jackson AJ. Role of metabolites in bioequivalency assessment. In: Jackson AJ, editor. Generics and bioequivalence. Boca Raton (FL): CRC Press, 1994: 49-65
30. Blume HH, Midha KK. Report of consensus meeting: Bio-International 94, conference on bioavailability, bioequivalence and pharmacokinetic studies. Eur J Pharm Sci 1995; 3: 113-24
31. Chen ML, Jackson AJ. The role of metabolites in bioequivalency assessment: II. drugs with linear pharmacokinetics and first-pass effect. Pharmaceutical Res 1995; 12: 700-8
32. Ezan E, Ardouin T, Landes BD, et al. Bioequivalence study of alpha-dihydroergocryptine: utility of metabolite evaluation. Int J Clin Pharmacol Ther 1996; 34: 32-7
33. Mascher HJ, Kikuta C, Millendorfer A, et al. Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. Int J Clin Pharmacol Ther 1997; 35: 9-13
34. Vergin H, Mahr G, Metz R, et al. Analysis of metabolites: a new approach to bioequivalence studies of spironolactone formulations. Int J Clin Pharmacol Ther 1997; 35: 334-40
35. Rosenbaum SE, Lam J. Bioequivalence parameters of parent drug and its first-pass metabolite: comparative sensitivity to sources of pharmacokinetic variability. Drug Dev Ind Pharm 1997; 23: 337-44
36. Mahmood I. Assessment of metabolites in bioequivalence studies: should bioequivalence criteria be applied on the sum of parent compound and metabolite? Int J Clin Pharmacol Ther 1998; 36: 540-4
37. Rosenbaum SE. Effect of variability in hepatic clearance on the bioequivalence parameters of a drug and its metabolite: simulations using a pharmacostatistical model. Pharm Acta Helv 1998; 73: 135-44
38. Jackson AJ. The role of metabolites in bioequivalency assessment: III. highly variable drugs with linear kinetics and first-pass effect. Pharm Res 2000; 17: 1432-6
39. Committee for Proprietary Medicinal Products, The European Agency for the Evaluation of Medicinal Products. Note for guidance on the investigation of bioavailability and bioequivalence [online]. Available from URL: http://www.emea.eu.int/pdfs/human/ewp/140198en.pdf [Accessed 2004 Jun 30]